FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD

Fakultät

Foto de FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD

Foto de National Taiwan University Hospital

National Taiwan University Hospital

Taipéi, Taiwán

Publikationen in Zusammenarbeit mit Forschern von National Taiwan University Hospital (5)

2024

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

2023

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
JAMA network open, Vol. 6, Núm. 11, pp. e2342107

2022

GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer
Future Oncology, Vol. 18, Núm. 34, pp. 3801-3813

2016

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

2015

Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
New England Journal of Medicine, Vol. 373, Núm. 3, pp. 232-242